ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad(The University of Texas at San Antonio Health Science Center), Barry Bernstein(AbbVie (United States)), Sandra Lovell(AbbVie (United States)), Barbara Da Silva‐Tillmann, Roger Trinh(AbbVie (United States)), Xavier Forns(Hospital Clínic de Barcelona), Stefan Zeuzem(Goethe University Frankfurt), Andrew Campbell(AbbVie (United States)), Kosh Agarwal(King's College - North Carolina), Eric M. Yoshida(Vancouver General Hospital), Heiner Wedemeyer(Medizinische Hochschule Hannover), Thomas Berg(Leipzig University of Applied Sciences), Christophe Hézode(Inserm), Kris V. Kowdley(Liver Institute Northwest), Mitchell L. Shiffman(Bon Secours Health System), Christine A. Collins(AbbVie (United States)), Thomas Podsadecki(AbbVie (United States))
Cited by 877
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k